MaxCyte Minutes Newsletter – Q4 2022
As the end of the year draws near, we’d like to take this opportunity to thank you for your support. At MaxCyte, we share your passion for enabling the discovery, development and manufacturing of next-generation medicines, harnessing the power of living cells to transform lives.
We are honored to support such a transformative industry, developing novel cell-based treatments that provide hope and new options to patients and their families worldwide.
All of us at MaxCyte, wish you a wonderful holiday season and happy new year!
Your MaxCyte Team
IN THE NEWS
MaxCyte Grand Opening Ceremony
We are happy to announce the signing of a new milestone partnership with Curamys. Curamys is a South Korean biotechnology company that develops cell & gene therapy using cell fusion technology to treat rare intractable diseases, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).
MaxCyte is honored to support Curamys’ effort to develop its cell-fusion technology for novel cell-based treatments that provide hope and new options to patients and their families by using our Flow Electroporation® technology and ExPERT™ platform.